Journal article
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement †
Abstract
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from being able to prescribe optimal therapy. Eighteen Canadian oncology clinicians from the medicine, nursing and pharmacy professions met to develop …
Authors
Sehdev SR; Rawson NSB; Aseyev OI; Buick CJ; Butler MO; Edwards S; Gill S; Gotfrit JM; Hsia CC; Juergens RA
Journal
Current Oncology, Vol. 31, No. 4, pp. 1803–1816
Publisher
MDPI
DOI
10.3390/curroncol31040136
ISSN
1198-0052